PMID- 33146469
OWN - NLM
STAT- MEDLINE
DCOM- 20211011
LR  - 20211011
IS  - 1756-185X (Electronic)
IS  - 1756-1841 (Linking)
VI  - 23
IP  - 12
DP  - 2020 Dec
TI  - Anti-carbamylated protein and peptide antibodies as potential inflammatory joint 
      biomarkers in the relatives of rheumatoid arthritis patients.
PG  - 1698-1706
LID - 10.1111/1756-185X.13977 [doi]
AB  - OBJECTIVE: Antibodies against carbamylated proteins/peptide (CarP) have been 
      associated with severity in rheumatoid arthritis (RA) patients. However, their 
      role in risk groups, specific targets and relation with periodontal disease (PD) 
      is uncertain yet. The aim of this study was evaluated the association between the 
      levels of anti-CarP with clinical manifestation, human leukocyte antigen (HLA) 
      alleles, periodontal activity markers, PD diagnosis, PD severity, and presence of 
      Porphyromonas gingivalis (P gingivalis) in relatives of patients with RA. 
      METHODS: One hundred and twenty-four individuals with a family history of RA in 
      first-degree relatives (FDR) and 124 healthy individuals gender- and age-matched, 
      RA activity was assessed. Antibodies against carbamylated protein anti-FCS-Carp 
      and 2 carbamylated peptides of fibrinogen were selected (anti-Ca-Fib2, 
      anti-Ca-Fib3). RESULTS: Anti-FCS-Carp-positive, anti-Ca-Fib2 and anti-Ca-Fib3 
      were more frequent in FDR than controls (25.0% vs 14.5%, 34.7% vs 15.3% and 33.1% 
      vs 11.3%, respectively). Anti-FCS-CarP were associated with the HLA-DRB1-SE* 1402 
      allele (P = .035) and highly sensitive C-reactive protein levels (P = .016), the 
      anti-Ca-Fib2 antibodies were associated with the HLA-DRB1-SE* 1501 allele (P = 
      .03), with non-SE* 0901 allele (P = .01), the anti-Ca-Fib3 was associated with 
      positive rheumatoid factor (P = .0012). The FDR condition was associated with the 
      presence of anti-Ca-Fib3 (odds ratio [OR] =4.7; 95% CI = 1.8-11.7; P = .001) and 
      painful joints (OR = 2.2; 95% CI = 1.01-4.68; P = .045); we also detected an 
      important trend toward the presence of P gingivalis (OR = 1.9; 95% CI = 0.9-3.7; 
      P = .062). CONCLUSION: The presence of anti-FCS-Carp, anti-Ca-Fib3 and 
      anti-Ca-Fib2 antibodies may have a role for these antibodies as early biomarkers 
      in the development of RA, probably including additional mechanisms related with 
      other non-SE alleles; the anti-peptide antibodies proposed in the present study 
      may represent a simpler way to identify antibodies directed to a specific target.
CI  - (c) 2020 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons 
      Australia, Ltd.
FAU - Chila-Moreno, Lorena
AU  - Chila-Moreno L
AD  - School of Dentistry, Cellular and Molecular Immunology Group/INMUBO, Universidad 
      El Bosque, Bogota, Colombia.
AD  - School of Medicine, Clinical Immunology Group, Universidad Militar Nueva Granada, 
      Bogota, Colombia.
FAU - Rodriguez, Luz-Stella
AU  - Rodriguez LS
AD  - Facultad de Medicina, Instituto de Genetica Humana, Pontificia Universidad 
      Javeriana, Bogota, Colombia.
FAU - Bautista-Molano, Wilson
AU  - Bautista-Molano W
AD  - School of Dentistry, Cellular and Molecular Immunology Group/INMUBO, Universidad 
      El Bosque, Bogota, Colombia.
AD  - School of Medicine, Clinical Immunology Group, Universidad Militar Nueva Granada, 
      Bogota, Colombia.
FAU - Bello-Gualtero, Juan-Manuel
AU  - Bello-Gualtero JM
AD  - School of Medicine, Clinical Immunology Group, Universidad Militar Nueva Granada, 
      Bogota, Colombia.
AD  - Rheumatology and Immunology Department, Clinical Immunology Group, Hospital 
      Militar Central, Bogota, Colombia.
FAU - Ramos-Casallas, Alejandro
AU  - Ramos-Casallas A
AD  - School of Dentistry, Cellular and Molecular Immunology Group/INMUBO, Universidad 
      El Bosque, Bogota, Colombia.
FAU - Romero-Sanchez, Consuelo
AU  - Romero-Sanchez C
AUID- ORCID: 0000-0002-6973-7639
AD  - School of Dentistry, Cellular and Molecular Immunology Group/INMUBO, Universidad 
      El Bosque, Bogota, Colombia.
AD  - School of Medicine, Clinical Immunology Group, Universidad Militar Nueva Granada, 
      Bogota, Colombia.
AD  - Rheumatology and Immunology Department, Clinical Immunology Group, Hospital 
      Militar Central, Bogota, Colombia.
LA  - eng
GR  - 2015-047/Hospital Militar Central, Bogota, Colombia/
GR  - 130865740792/Departamento Administrativo de Ciencia, Tecnologia e 
      Innovacion,Bogota, Colombia/
GR  - Universidad El Bosque, Bogota, Colombia/
PT  - Journal Article
DEP - 20201104
PL  - England
TA  - Int J Rheum Dis
JT  - International journal of rheumatic diseases
JID - 101474930
RN  - 0 (Autoantibodies)
RN  - 0 (Biomarkers)
RN  - 0 (Carbamates)
SB  - IM
MH  - Adult
MH  - Arthritis, Rheumatoid/diagnosis/*immunology/metabolism
MH  - Autoantibodies/*immunology
MH  - Biomarkers/metabolism
MH  - Carbamates/*immunology/metabolism
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - Inflammation/immunology/metabolism
MH  - Male
MH  - Protein Carbamylation
OTO - NOTNLM
OT  - antibodies
OT  - carbamylation
OT  - rheumatoid arthritis
EDAT- 2020/11/05 06:00
MHDA- 2021/10/12 06:00
CRDT- 2020/11/04 08:45
PHST- 2020/06/10 00:00 [received]
PHST- 2020/09/01 00:00 [revised]
PHST- 2020/09/07 00:00 [accepted]
PHST- 2020/11/05 06:00 [pubmed]
PHST- 2021/10/12 06:00 [medline]
PHST- 2020/11/04 08:45 [entrez]
AID - 10.1111/1756-185X.13977 [doi]
PST - ppublish
SO  - Int J Rheum Dis. 2020 Dec;23(12):1698-1706. doi: 10.1111/1756-185X.13977. Epub 
      2020 Nov 4.